Table 3.
Clinical outcomes for 3-year MACE in study population.
| Parameter | Total (N = 153) | High IMR (N = 52) | Low IMR (N = 101) | P value |
|---|---|---|---|---|
| 3-years MACE, n (%)∗ | 17 (11.1%) | 8 (15.4%) | 9 (8.9%) | 0.279 |
| CV death | 3 (2.0%) | 3 (5.8%) | 0 (0.0%) | 0.038 |
| Hospitalization for HF | 1 (0.7%) | 1 (1.9%) | 0 (0.0%) | 0.340 |
| TLR | 7 (4.6%) | 1 (1.9%) | 6 (5.9%) | 0.424 |
| Stent thrombosis | 3 (2.0%) | 1 (1.9%) | 2 (2.0%) | 1.000 |
| Nonfatal MI | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1.000 |
| Stroke | 3 (2.0%) | 2 (3.8%) | 1 (1.0%) | 0.267 |
| Major bleeding | 2 (1.3%) | 2 (3.8%) | 0 (0.0%) | 0.114 |
CV, cardiovascular; HF, heart failure; IMR, index of microcirculatory resistance; MACE, major advanced cardiac events; MI, myocardial infarction; TLR, target lesion revascularization. ∗MACE was defined as composite of CV death, hospitalization because of HF, TLR, stent thrombosis, nonfatal MI, stroke, and major bleeding.